Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

Next Previous
Trial Profile

Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gadopiclenol (Primary) ; Gadobutrol
  • Indications Advanced breast cancer; CNS disorders; Head and neck cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Uterine cancer
  • Focus Diagnostic use; Registrational
  • Acronyms PROMISE
  • Sponsors Guerbet

Most Recent Events

  • 17 Apr 2026 According to a Bracco media release, the Health Canada has approved VUEWAY injection (gadopiclenol), a macrocyclic gadolinium-based contrast agent (GBCA), for use in contrast-enhanced magnetic resonance imaging (CE-MRI).
  • 11 Dec 2023 According to a Guerbet media release, Primary endpoint (Lesion visualization criteria for gadopiclenol-enhanced MRI compared to gadobutrol-enhanced MRI)has been met.
  • 11 Dec 2023 According to a Guerbet media release, Primary endpoint (Lesion visualization criteria for gadopiclenol-enhanced MRI compared to unhenhanced MRI) has been met.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top